JMI LABS IS NOW PART OF LEARN MORE

Activity of Tigecycline Tested against a Worldwide Collection of Vancomycin-Resistant Enterococci

Activity of Tigecycline Tested against a Worldwide Collection of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Susceptibility of Gram-positive Organisms Isolated in Latin American Hospitals: Evaluation of the Emergence and Dissemination of Vancomycin-Resistant Enterococci

Antimicrobial Susceptibility of Gram-positive Organisms Isolated in Latin American Hospitals: Evaluation of the Emergence and Dissemination of Vancomycin-Resistant Enterococci, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Susceptibility Pattern of Gram-positive Organisms Isolated in Australian Medical Centers (2004, 2006-2007): Results from a Multi-Center Prospective Surveillance Program

Susceptibility Pattern of Gram-positive Organisms Isolated in Australian Medical Centers (2004, 2006-2007): Results from a Multi-Center Prospective Surveillance Program, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Decreasing Susceptibility Rates Among Acinetobacter spp. Clinical Isolates Collected Worldwide (2005-2008)

Decreasing Susceptibility Rates Among Acinetobacter spp. Clinical Isolates Collected Worldwide (2005-2008), Lead author: Mendes RE, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Emergence of blaOXA-48 among Enterobacter cloacae in Argentina and its Prevalence among Carbapenem Non-Susceptible Enterobacteriaceae

Emergence of blaOXA-48 among Enterobacter cloacae in Argentina and its Prevalence among Carbapenem Non-Susceptible Enterobacteriaceae, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Emergence of OXA-48 Carbapenemases among Klebsiella spp. from India

Emergence of OXA-48 Carbapenemases among Klebsiella spp. from India, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

High Prevalence of CTX-M-Producing Isolates and Emergence of KPC-Encoding Genes in the Western United States

High Prevalence of CTX-M-Producing Isolates and Emergence of KPC-Encoding Genes in the Western United States, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Diversity of Acquired Ribosomal RNA Methylase Genes Encoding Aminoglycoside Resistance in the Asia-Pacific Region

Diversity of Acquired Ribosomal RNA Methylase Genes Encoding Aminoglycoside Resistance in the Asia-Pacific Region, Lead author: Bell JM, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Recommended Ulifloxacin MIC Quality Control Ranges for Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study Design

Recommended Ulifloxacin MIC Quality Control Ranges for Campylobacter jejuni ATCC 33560 Using a CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Streit J, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Initial Quality Control Ranges for CEM-102 (Fusidic Acid) Using the CLSI Multi-Laboratory M23-A3 Study Design

Initial Quality Control Ranges for CEM-102 (Fusidic Acid) Using the CLSI Multi-Laboratory M23-A3 Study Design, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Recently Approved Tigecycline Susceptibility Breakpoints for S. pneumoniae and H. influenzae: Do Broth Microdilution and Disk Diffusion Results Agree?

Recently Approved Tigecycline Susceptibility Breakpoints for S. pneumoniae and H. influenzae: Do Broth Microdilution and Disk Diffusion Results Agree?, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Minocycline Using Gram-Positive and Gram-Negative Organisms

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Minocycline Using Gram-Positive and Gram-Negative Organisms, Lead author: Knapp C, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Epidemiologic Detection Of Carbapenemase-producing Klebsiella spp. By EUCAST or CLSI Clinical Breakpoints

Epidemiologic Detection Of Carbapenemase-producing Klebsiella spp. By EUCAST or CLSI Clinical Breakpoints, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Iclaprim Using Fastidious and Non-Fastidious Gram-Positive Organisms

A Multi-Site Study Comparing an 18-24h Sensititre Susceptibility System to the CLSI Broth Microdilution Method for Iclaprim Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Bastulli, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

A Multi-Site Study Comparing an 18-24h Susceptibility System to the CLSI Broth Microdilution Method for Telavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms

A Multi-Site Study Comparing an 18-24h Susceptibility System to the CLSI Broth Microdilution Method for Telavancin Using Fastidious and Non-Fastidious Gram-Positive Organisms, Lead author: Holliday, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of Ceftaroline against Emerging Serotypes of Streptococcus pneumoniae

Activity of Ceftaroline against Emerging Serotypes of Streptococcus pneumoniae, Lead author: Jacobs, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Streptococci from United States and European Medical Centers: Results from the Ceftaroline Longitudinal Assessment of Spectrum and Susceptibility (CLASS) Program

Antimicrobial Activity of Ceftaroline Tested against Streptococci from United States and European Medical Centers: Results from the Ceftaroline Longitudinal Assessment of Spectrum and Susceptibility (CLASS) Program, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride Compound : A Gram-negative Antimicrobial

In Vitro Activity and In Vivo Efficacy of (S)-3(aminomethyl)benzo[c][1,2]oxaborol-1(3H)-ol hydrochloride Compound : A Gram-negative Antimicrobial, Lead author: Alley, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Spectrum and Activity of Ceftaroline Combined with NXL-104 Tested against a Challenge Collection of Pathogens with Well Characterized Resistances

Spectrum and Activity of Ceftaroline Combined with NXL-104 Tested against a Challenge Collection of Pathogens with Well Characterized Resistances, Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms

Bactericidal Activity of Ceftaroline Combined with NXL-104 against Critical Targeted Organisms Possessing Various Resistance Mechanisms, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans

In Vitro Antibacterial Spectrum of BC-3205, a Novel Pleuromutilin Derivative for Oral Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans

In Vitro Antibacterial Spectrum of BC-7013, a Novel Pleuromutilin Derivative for Topical Use in Humans, Lead author: Ivezic-Schoenfeld, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis

Activity of the Novel Cephalosporin CXA-101 Tested in Combination with Tazobactam Against Cephalosporin-resistant Enterobacteriaceae, P. aeruginosa and B. fragilis, Lead author: Sader HS, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia

First Year Antimicrobial Surveillance Results for CEM-101, a Novel Fluoroketolide with Potent Activity Against Pathogens Associated with Community-acquired Bacterial Pneumonia, Lead author: Jones RN, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection

Activity of CEM-101, a Novel Fluoroketolide, Tested Against Invasive Isolates of N. meningitidis from a Worldwide Collection, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe

Activity of ACHN-490, a Novel Neoglycoside Antibiotic, against Complicated Urinary Tract Infection Pathogens From the United States and Europe, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes

Antimicrobial Activity of ACHN-490, a Neoglycoside, Tested Against a Contemporary Collection of Clinical Isolates Including Problematic Antimicrobial-Resistant Phenotypes, Lead author: Biedenbach DJ, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Clinical Outcomes of Infections Caused by Extended-Spectrum &#223-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility

Clinical Outcomes of Infections Caused by Extended-Spectrum &#223-Lactamase (ESBL)-Producing Bacteria with Reduced Carbapenem Susceptibility, Lead author: Le, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections

Correlation of Baseline Methicillin-Resistant Staphylococcus aureus (MRSA) Isolate Characteristics with Clinical Outcome from a Randomized Phase 4 Clinical Trial of Complicated Skin and Soft Tissue Infections, Lead author: Hogan, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp.

Low Prevalence of fks1 Hotspot 1 Mutations in a Worldwide Collection of Candida spp., Lead author: Castanheira M, presented at 49th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 12 – 15, 2009, San Francisco, CA

Assessment of Non-Antibiotic Therapeutic Agent Interactions on the Potency of Orally Administered Vancomycin

Assessment of Non-Antibiotic Therapeutic Agent Interactions on the Potency of Orally Administered Vancomycin, Lead author: Sader HS, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): Linezolid Global In Vitro Susceptibility Analyses

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program 2008 (Europe, Latin America, Canada, Asia Pacific): Linezolid Global In Vitro Susceptibility Analyses, Lead author: Ross JE, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program 2008: USA Surveillance Report

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program 2008: USA Surveillance Report, Lead author: Jones RN, presented at 109th annual American Society for Microbiology General Meeting (ASM), May 17 – 21, 2009, Philadelphia, PA

Activity of CEM-101 Tested Against Emerging Telithromycin-Resistant Beta-Haemolytic Streptococci (BHS)

Activity of CEM-101 Tested Against Emerging Telithromycin-Resistant Beta-Haemolytic Streptococci (BHS), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Novel PER-variant ß-lactamase identified in Providencia rettgeri strain from the United States (USA): Report from the SENTRY Antimicrobial Surveillance Program

Novel PER-variant ß-lactamase identified in Providencia rettgeri strain from the United States (USA): Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Pharmacodynamically-linked Variable for the Combination of Ceftaroline plus Novexel104

Pharmacodynamically-linked Variable for the Combination of Ceftaroline plus Novexel104, Lead author: Drusano GL, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Update on the Spectrum and Potency of Tigecycline Tested against 7,133 Gram-positive and -negative Pathogens from 13 Countries (2008)

Update on the Spectrum and Potency of Tigecycline Tested against 7,133 Gram-positive and -negative Pathogens from 13 Countries (2008), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Worldwide activity of Tigecycline against Community-acquired Respiratory Tract Infection Pathogens Collected During 2006-2008

Worldwide activity of Tigecycline against Community-acquired Respiratory Tract Infection Pathogens Collected During 2006-2008, Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Report of Linezolid Resistance from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific)

Report of Linezolid Resistance from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program (Europe, Latin America, Asia Pacific), Lead author: Ross JE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Update on daptomycin activity and spectrum when tested against Gram-positive strains collected in European medical centres (2007-2008)

Update on daptomycin activity and spectrum when tested against Gram-positive strains collected in European medical centres (2007-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Potent Antimicrobial Activity of Daptomycin Tested against Staphylococcus aureus with Vancomycin MIC of 2 mg/L Isolated in United States and European hospitals (2006-2008)

Potent Antimicrobial Activity of Daptomycin Tested against Staphylococcus aureus with Vancomycin MIC of 2 mg/L Isolated in United States and European hospitals (2006-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Prevalence of Extended-spectrum Beta-lactamases among Enterobacteriaceae Strains from the United States (USA; 2007) and Correlation with KPC Carbapenemases

Prevalence of Extended-spectrum Beta-lactamases among Enterobacteriaceae Strains from the United States (USA; 2007) and Correlation with KPC Carbapenemases, Lead author: Castanheira M, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Prevalence and Antimicrobial Susceptibility Patterns of Methicillin-resistant S. aureus and Vancomycin-resistant E. faecium Causing Bloodstream Infections in European Hospitals (2005-2008)

Prevalence and Antimicrobial Susceptibility Patterns of Methicillin-resistant S. aureus and Vancomycin-resistant E. faecium Causing Bloodstream Infections in European Hospitals (2005-2008), Lead author: Sader HS, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Telavancin Activity against S. aureus and Coagulase-negative Staphylococci Collected from Clinical Infections in Europe (2007-2008)

Telavancin Activity against S. aureus and Coagulase-negative Staphylococci Collected from Clinical Infections in Europe (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Antimicrobial Activity of Telavancin Tested against Streptococcal Species Isolates Collected from European Medical Centres (2007-2008)

Antimicrobial Activity of Telavancin Tested against Streptococcal Species Isolates Collected from European Medical Centres (2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Telavancin Antimicrobial Activity when Tested against Enterococci and Uncommonly Isolated Gram-positive Species (European Sample for 2007-2008)

Telavancin Antimicrobial Activity when Tested against Enterococci and Uncommonly Isolated Gram-positive Species (European Sample for 2007-2008), Lead author: Rhomberg PR, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007)

Ten-year trend in aminoglycoside resistance from a worldwide collection of Gram-negative pathogens (1998-2007), Lead author: Biedenbach DJ, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Surveying Aminoglycoside Resistance Mechanisms: a Tool for the Development of Neoglycosides

Surveying Aminoglycoside Resistance Mechanisms: a Tool for the Development of Neoglycosides, Lead author: Armstrong, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Anti-pseudomonal Activity of Piperacillin/tazobactam: More than a Decade of Experience from the SENTRY Antimicrobial Surveillance Program (1997-2007)

Anti-pseudomonal Activity of Piperacillin/tazobactam: More than a Decade of Experience from the SENTRY Antimicrobial Surveillance Program (1997-2007), Lead author: Jones RN, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland

Detection of cfr-carrying Staphylococcus spp. Isolates Recovered from Blood Cultures in a Spanish Hospital During a Phase III Clinical Trial of Topical Omiganan 1% Gel Versus 10% Povidone Iodine

Detection of cfr-carrying Staphylococcus spp. Isolates Recovered from Blood Cultures in a Spanish Hospital During a Phase III Clinical Trial of Topical Omiganan 1% Gel Versus 10% Povidone Iodine, Lead author: Mendes RE, presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 16 – 19, 2009, Helsinki, Finland